Search

Displaying results 1391 - 1400 of 6949 in total
  1. Target

    Interleukin-12 receptor subunit beta-2

    go.drugbank.com/bio_entities/BE0018860
    TargetHumans

    Receptor for interleukin-12. This subunit is the signaling component coupling to the JAK2/STAT4 pathway. Promotes the proliferation of T-cells as well as NK cells.

    Polypeptides: Interleukin-12 receptor subunit beta-2Synonyms: IL-12 receptor subunit beta-2
  2. Target

    Taste receptor type 2 member 10

    go.drugbank.com/bio_entities/BE0020463
    TargetHumans

    Gustducin-coupled strychnine receptor implicated in the perception of bitter compounds in the oral cavity and the gastrointestinal tract.

    Polypeptides: Taste receptor type 2 member 10Synonyms: Taste receptor family B member 2
  3. Target

    Short transient receptor potential channel 4

    go.drugbank.com/bio_entities/BE0020751
    TargetHumans

    Forms a receptor-activated non-selective calcium permeant cation channel (PubMed:11042129, PubMed:11713258, PubMed:16144838, PubMed:39478185).

    Polypeptides: Short transient receptor potential channel 4
  4. Target

    Short transient receptor potential channel 5

    go.drugbank.com/bio_entities/BE0021113
    TargetHumans

    Forms a receptor-activated non-selective calcium permeant cation channel (PubMed:16284075, PubMed:38959890, PubMed:37137991).

    Polypeptides: Short transient receptor potential channel 5Synonyms: Transient receptor protein 5
  5. Target

    Taste receptor type 2 member 14

    go.drugbank.com/bio_entities/BE0023216
    TargetHumans

    Gustducin-linked G protein-coupled receptor that plays a role in the perception of bitterness (PubMed:38600377, PubMed:38776963). … The activity of this receptor stimulates GNAT3, activating the gustducin G protein pathway (PubMed:38600377, PubMed:38776963).

    Polypeptides: Taste receptor type 2 member 14Synonyms: Taste receptor family B member 1
  6. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    therapy option in combination with [sofosbuvir] for the treatment of HCV genotypes 1a, 1b, 4, 5, and 6 [L852]. … Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as ledipasvir.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    Sulbactam

    go.drugbank.com/drugs/DB09324
    ApprovedInvestigational

    [L50131] When given in combination with β-lactam antibiotics, sulbactam produces a synergistic effect as it blocks the enzyme responsible for drug resistance by hydrolyzing β-lactams.[A263296]

    Mixtures: SULBACTER POWDER FOR SOLUTION FOR INJECTION or INFUSION 3g/vial, SULBACTER POWDER FOR SOLUTION FOR INJECTION or INFUSION 1.5g/vialCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  8. Drug

    Chromic chloride

    go.drugbank.com/drugs/DB09129
    Approved

    Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).

    Mixtures: Addaven Concentrate for Solution for Infusion, ADDAVEN CONCENTRATE FOR SOLUTION FOR INFUSION
  9. Drug

    Lonafarnib

    go.drugbank.com/drugs/DB06448
    ApprovedInvestigational

    [L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549] … A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FTI), which reduces the farnesylation of numerous cellular proteins, including progerin; as progerin farnesylation is important for

  10. Drug

    Scopolamine

    go.drugbank.com/drugs/DB00747
    ApprovedInvestigational

    [A228423, A228758] As a result of its anticholinergic effects, scopolamine is being investigated for diverse therapeutic applications; currently, it is approved for the prevention of nausea and vomiting